New scientific findings from Trinity College Dublin reveal how tumours evade chemotherapy by slipping into a zombie-like state, a discovery that exposes a fresh weakness in cancer cells. Researchers established that certain proteins enable malignant tissue to survive aggressive drug treatments, ultimately hijacking the body’s natural tissue repair systems to aid their recovery.
Blocking Tumour Defences in Dublin Laboratories
Scientists working in the Smurfit Institute of Genetics uncovered the mechanism behind how cancers survive initial medical intervention. When standard chemotherapy inflicts DNA damage on a tumour, the affected cells can avoid complete destruction by triggering a process known as premature senescence. Instead of dying off, these cells swell to nearly ten times their normal size, stop dividing, and begin pumping out inflammatory signals that mimic damaged tissue. This trickery draws in the immune system, which mistakenly supplies the rogue cells with oxygen and nutrients to aid recovery rather than destroying them.
The research team identified that molecules called Inhibitor of Apoptosis Proteins (IAPs) drive this survival tactic. These proteins neutralize death receptors that are normally switched on by chemotherapy-induced DNA damage. Discovering how tumours can evade the cell-killing effects of chemotherapy and enter senescence is an important and challenging problem,
said Smurfit Professor of Medical Genetics Seamus Martin, who led the work alongside postdoctoral research fellow Dr Gokhan Gunay.
Cancers have long been described as wounds that do not heal due to their manipulation of immune repair pathways, but the exact switching mechanism remained poorly understood until now. The Trinity study demonstrates that these senescent cancer cells rely heavily on IAPs to maintain their zombie-like existence. Because these surviving cells are so dependent on IAPs, administering specific compounds known as IAP antagonists can strip away their defences.
These new findings suggest ways in which we may be able to lower the defences of tumours by neutralising IAPs after the delivery of chemotherapeutic drugs, which should block their entry to senescence and kill more cells of the tumour,Professor Martin explained.Smurfit Institute of Genetics at Trinity College Dublin
By applying these neutralising compounds after chemotherapy, researchers successfully reactivated the death receptor self-destruct program within the dormant cells. This targeted approach selectively eliminates the lingering cells that typically help tumours bounce back after treatment.
Funding and Publication Details
The peer-reviewed study, supported by the European Research Council and Research Ireland, has been published in the journal Science Advances. The findings map out a promising route for developing advanced therapies that lower tumour defences and improve patient survival rates.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.